| Project/Area Number |
17K10677
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Fujita Health University (2020)
Iwate Medical University (2017-2019) |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
佐々木 章 岩手医科大学, 医学部, 教授 (40275540)
|
|---|
| Project Period (FY) |
2017-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2019: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2018: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | SP細胞 / 肝再生 / 脾摘 / Side population細胞 / 肝外細胞注入療法 / 脾臓 / 肝切除 / 肝不全 / 大量肝切除 / 門脈圧 / 組織幹細胞 |
|---|
| Outline of Final Research Achievements |
Stem cell transplantation is attracting attention as an alternative therapy for liver transplantation. SP cells are cells capable of excreting the DNA-binding dye Hoechst 33342 and are present in various organs. Previous studies have found that the spleen is the largest reservoir of SP cells among all organs. In this study, we focused on spleen SP cells and verified their usefulness as transplanted cells by investigating whether long-term storage by freezing is possible. were frozen and the abundance of SP cells was measured for each period. SP cells consistently had a higher survival rate after cryopreservation than MP cells.
When SP cells were considered as cell transplant candidates, they were shown to have the advantageous property of being resistant to freezing stress.
|
| Academic Significance and Societal Importance of the Research Achievements |
今回我々はSP細胞の入手源として脾臓に着目した．過去の文献では，ラット大量肝切除モデルに脾臓摘出を加えることで至適門脈圧へのコントロールが可能であり，肝再生が促進されたという報告がある. 今後，摘出した脾臓より分離したSP細胞を大量肝切除モデルに移植し，その生着率や肝再生への寄与などを検討していきたい．肝切除後に脾摘を行い，その脾臓よりSP細胞を分離して自家移植し，さらに肝再生を惹起する至適門脈圧に調整することが可能となれば，中長期的には再生医療における選択的細胞増殖法の開発への足がかりや切除不能肝腫瘍の究極的治療の開発につながると期待している．
|
